Citations

Clear

6273 citation(s) found for "To, Andrew".

Evaluating large language models in echocardiography reporting: opportunities and challenges
Chao, Chieh-Ju, Banerjee, Imon , Arsanjani, Reza , Ayoub, Chadi , Tseng, Andrew S. , Delbrouck, Jean-Benoit, Kane, Garvan C. , López-Jiménez, Francisco , Oh, Jae K. , Fei-Fei, Li , Adeli, Ehsan, Tseng, A S , Erickson, Bradley, Banerjee, Imon , Lopez-Jimenez, Francisco , Arsanjani, Reza , Chao, Chieh‐Ju , Attia, Zachi I. , Erickson, Bradley J. , Adeli, Ehsan , Langlotz, Curtis P.

Mayo Clinic

European Heart Journal - Digital Health | November 27, 2024 | Volume: 6 | Issue: 3 | Pages: 326-339

10.1093/ehjdh/ztae086 | PMID 40395412 Get It

Abstract Aims The increasing need for diagnostic echocardiography tests presents challenges in preserving the quality and promptness of reports. While Large Language Models (LLMs) have proven effective in summarizing clinical texts, their application in echo remains underexplored. Methods and results Adult echocardiography studies, conducted at the Mayo Clinic from 1 January 2017 to 31 December 2017, were categorized into two groups: development (all Mayo locations except Arizona) and Arizona validation sets. We adapted open-source LLMs (Llama-2, MedAlpaca, Zephyr, and Flan-T5) using In-Context Learning and Quantized Low-Rank Adaptation fine-tuning (FT) for echo report summarization from ‘Findings’ to ‘Impressions.’ Against cardiologist-generated Impressions, the models’ performance was assessed both quantitatively with automatic metrics and qualitatively by cardiologists. The development dataset included 97 506 reports from 71 717 unique patients, predominantly male (55.4%), with an average age of 64.3 ± 15.8 years. EchoGPT, a fine-tuned Llama-2 model, outperformed other models with win rates ranging from 87% to 99% in various automatic metrics, and produced reports comparable to cardiologists in qualitative review (significantly preferred in conciseness (P < 0.001), with no significant preference in completeness, correctness, and clinical utility). Correlations between automatic and human metrics were fair to modest, with the best being RadGraph F1 scores vs. clinical utility (r = 0.42) and automatic metrics showed insensitivity (0–5% drop) to changes in measurement numbers. Conclusion EchoGPT can generate draft reports for human review and approval, helping to streamline the workflow. However, scalable evaluation approaches dedicated to echo reports remains necessary.
Challenges in renally eliminated medication use: Evaluating cystatin C and serum creatinine eGFR discordance
Hernandez, Brandy N., Wieruszewski, Patrick M. , Barreto, Jason N. , Cole, Kristin C., Damani, Shivam, Kane‐Gill, Sandra L. , Kelly, Ellen , Teaford, Hilary R. , Zand, Jaleh , Frazee, Erin N. , Mara, Kristin C. , Frazee, Erin N , Kane-Gill, Sandra L , Mara, Kristin C , Wieruszewski, Patrick M , Kashani, Kianoush , Kelly, Ellen, Rule, Andrew D.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | November 27, 2024 | Volume: 44 | Issue: 12 | Pages: 898-906

10.1002/phar.4627 | PMID 39601345 Get It

AbstractBackgroundAccurately estimating glomerular filtration rate (GFR) is crucial for dosing medications in hospitalized patients. Due to limitations of serum creatinine for GFR estimation, serum cystatin C (CysC) has been explored as an alternative functional kidney biomarker. This study assessed discordance between eGFRCr and eGFRCysC in a large sample of hospitalized patients and examined the frequency of renally eliminated medications affected by eGFR discordance.MethodsThis multisite historical study included adults hospitalized between 2011 and 2023 with CysC and serum creatinine reported within 24 h of each other. The first concurrent biomarker pair for each patient was analyzed. eGFR discordance and use of renally eliminated medications were described.Results17,718 hospitalized patients with concurrent creatinine and CysC assessments were included. The median eGFRCr was 65 mL/min, and the eGFRCysC was 46 mL/min. The median absolute difference of eGFRCr−eGFRCysC was 15 mL/min, and 7972 patients (45%) had a > 30% absolute difference. There was a significantly greater percentage of patients with an eGFR <30 mL/min based on eGFRCysC (26%) compared to eGFRCr (15%) (p < 0.001). Patients were prescribed an average of 20 medications in the 24 h surrounding the concurrent biomarker assessment. Renally eliminated medications accounted for 39% ± 13% of medication orders, and 80% of patients with eGFR discordance were prescribed five or more renally eliminated medications.ConclusionSubstantial eGFR discordance between eGFRCysC and eGFRCr was observed in hospitalized patients, which directly affects the dosing of renally eliminated medications. Further research is needed to optimize the pharmacotherapy of renally eliminated medications with discordant GFR assessments to improve medication safety and effectiveness.
Surgical Trends in Chronic Pancreatitis From 2014 to 2021
Turunen, Arto , Garg, Sushil Kumar , Turunen, Andrew

Mayo Clinic

Pancreas | November 26, 2024 | Volume: 54 | Issue: 4 | Pages: e310-e316

10.1097/mpa.0000000000002438 | PMID 39591530 Get It

Objectives: We analyzed annual surgical trends for benign chronic pancreatitis (CP), studying specifically mortality, morbidity, and pancreatic fistula rates. We also aimed to identify predictors of pancreatic fistula formation. Materials and Methods: For this analysis, we used data from the American College of Surgeons National Surgical Quality Improvement Program from 2014 to 2021. The study included patients who underwent surgery for benign CP. Data collected included patient demographics, preoperative variables, and postoperative outcomes. Data were analyzed with univariate and multivariate analyses, with significance defined as P ≤ 0.05. Results: Over the study period, the number of pancreatic surgical procedures increased by 49.3%, although surgery specifically for CP declined by 31.7%. The rate of pancreatic fistula formation decreased 44.9%, and mortality decreased 31.9%. Significant predictors of a pancreatic fistula included no diabetes, preoperative sepsis, soft texture of the pancreatic gland, and greater patient weight. Conclusion: Surgery for benign CP decreased substantially despite the established efficacy of surgical intervention for long-term pain management. The concurrent decline in mortality and rates of pancreatic fistula formation suggest advances over the study years in surgical and postoperative care.
A Simple Clinical Predictive Model for Arthroscopic Mobility of Osteochondritis Dissecans Lesions of the Knee
Milewski, Matthew D., Milewski, Matthew D., Miller, Patricia E., Gossman, Emma C. , Coene, Ryan P. , Tompkins, Marc , Anderson, Christian N. , Bauer, Kathryn, Busch, Michael T., Carey, James L. , Ellermann, Jutta , Ellis, Henry B. , Erickson, John , Ganley, Theodore J. , Heyworth, Benton E. , Latz, Kevin, Lyon, Roger, Mayer, Stephanie W. , Milewski, Matthew D. , Milewski, Matthew D., Miller, Patricia E., Nepple, Jeffrey J. , Nguyen, Jie C. , Nissen, Carl W. , Paterno, Mark V. , Pennock, Andrew T. , Perkins, Crystal A. , Polousky, John D. , Saluan, Paul, Shea, Kevin G. , Wall, Eric J. , Willimon, Clifton, Wilson, Philip L., Wright, Rick W. , Zbojniewicz, Andy, Myer, Gregory D , Milewski, Matthew D., Milewski, Matthew D., Miller, Patricia E., Carsen, Sasha , Chambers, Henry G. , Edmonds, Eric W. , Fabricant, Peter D , Green, Daniel W , Hui, James Hoi Po , Kocher, Mininder Singh , Krych, Aaron J. , Milewski, Matthew D., Miller, Patricia E., Nelson, Bradley J. , Pace, J Lee , Weiss, Jennifer M., Wilson, Philip L. , Myer, Gregory D.

Mayo Clinic

The American Journal of Sports Medicine | November 25, 2024 | Volume: 52 | Issue: 14 | Pages: 3543-3550

10.1177/03635465241296133 | PMID 39584729 Get It

Background: Osteochondritis dissecans (OCD) of the knee is a focal idiopathic alteration of subchondral bone and/or its precursor with risk for instability and disruption of adjacent cartilage. Treatment options focused on preventing premature osteoarthritis vary depending on multiple patient and lesion characteristics, including lesion mobility. Purpose: To differentiate lesion mobility before arthroscopy using a multivariable model that includes patient demographic characteristics and physical examination findings. Study Design: Cohort study (Diagnosis); Level of evidence, 2. Methods: Demographic, preoperative physical examination, and radiographic data were collected from a multicenter national prospective cohort of patients with OCD of the knee. Inclusion criteria included patients <19 years of age and patients with arthroscopically confirmed mobility status based on the Research on Osteochondritis Dissecans of the Knee arthroscopy classification. Multivariable logistic regression analysis using stepwise model selection was used to determine factors associated with the likelihood of a mobile versus an immobile lesion. A 75% partition of the data was used for model training, and 25% was used as a validation cohort. Quantitative model fit statistics were computed using the holdout data, including sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC), along with the corresponding 95% CI. Results: A total of 407 patients in the prospective cohort met inclusion criteria, and 62% were male. The mean ± SD age was 13.7 ± 2.2 years, height 161.8 ± 5.3 cm, and weight 59.2 ± 42.2 kg. Arthroscopic evaluation yielded 235 immobile and 172 mobile lesions. Multivariable analysis determined that the best model to predict lesion mobility included chronologic age ≥14 years ( P < .001), effusion on physical examination ( P < .001), and any loss of range of motion on physical examination ( P = .07), while controlling for male sex ( P = .38) and weight >54.4 kg ( P = .12). In the 25% holdout validation sample (n = 102), a sensitivity of 83%, a specificity of 82%, and an AUC of 0.89 (95% CI, 0.82-0.95) were achieved with these predictive factors. Conclusion: Age, effusion, and loss of motion can predict knee OCD lesion mobility at the time of arthroscopy. Education about lesion mobility can help with surgical planning and patient and family counseling.
LTBK-01. PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
Colman, Howard , Walbert, Tobias , Lassman, Andrew B. , Kizilbash, Sani H. , Kamiya-Matsuoka, Carlos, Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren, Butowski, Nicholas , Forsyth, Peter, Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Levin, Victor A. , Kizilbash, Sani H , Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Eoli, Marica , Peereboom, David M. , Strowd, Roy E. , Pellerino, Alessia , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1301 Get It

Abstract BACKGROUND Recurrent anaplastic astrocytoma (AA), a grade 3 brain cancer, remains an unmet medical need. STELLAR was a phase III randomized, open-label trial of eflornithine (ornithine decarboxylase inhibitor) with lomustine versus lomustine alone, originally for patients with recurrent AA. However, as the WHO definition of AA evolved during trial conduct (e.g., excluding IDH wild-type disease), we determined results in both the original ITT population and by revised molecularly defined WHO 2021 diagnoses in pre-planned analyses. METHOD Key eligibility: age ≥ 18, AA (2016 WHO criteria), first recurrence ≥ 6 months after radiation and temozolomide, KPS ≥ 70, no imaging findings consistent with grade 4 glioblastoma. Stratification: IDH, age, resection extent, and geography. Patients were randomized to Arm A: eflornithine (2.8 g/m2 TID Q 2/3 weeks) with lomustine (90 mg/m2 Q 6 weeks) or Arm B: lomustine (110 mg/m2 Q 6 weeks). Primary endpoint was OS. The pre-specified hazard ratio (HR) goal was 0.667 based on projected median OS (mOS) increase to 18 months from 12 months. RESULTS 343 pts (172/171 Arms A/B) were randomized (105 sites, 8 countries). ITT analysis found no difference between arms (mOS 23.4 vs. 20.3 months, HR = 0.94). However, a pre-specified subset analysis in IDH mutant, 2021 WHO-defined grade 3 astrocytoma (n=194), showed significant improvement with eflornithine (mOS 34.9 vs. 23.5 months, HR = 0.64, log rank p = 0.016) and PFS (15.8 vs. 7.2 months, HR = 0.58, log rank p = 0.015). No difference was observed in the IDH wild-type subset. AEs were consistent with historic data. CONCLUSION There was no difference in OS between arms in the ITT analysis. However, medically meaningful and statistically significant OS and PFS benefits were observed with eflornithine in the pre-planned analysis of patients with molecularly defined 2021 WHO CNS grade 3 astrocytoma.
ProtPipe: A Multifunctional Data Analysis Pipeline for Proteomics and Peptidomics
Li, Ziyi , Weller, Cory A. , Shah, Syed Islamuddin , Johnson, Nicholas L. , Hao, Ying , Roberts, Jessica P. , Guha, Deyaan, Bereda, Colleen , Klaisner, Sydney, Machado, Pedro , Zanovello, Matteo , Prudencio, Mercedes , Staff, Nathan P. , Fratta, Pietro , Petrucelli, Leonard , Cookson, Mark , Ward, Michael E. , Singleton, Andrew , Nalls, Mike A. , Fratta, Pietro , Shah, Syed I , Jarreau, Paige B , Roberts, Jessica , Guha, Deyaan , Bereda, Colleen , Klaisner, Sydney , Machado, Pedro M , Zanovello, Matteo , Prudencio, Mercedes , Oskarsson, Björn , Staff, Nathan P , Dickson, Dennis W , Fratta, Pietro , Petrucelli, Leonard , Narayan, Priyanka , Ward, Michael E , Singleton, Andrew B , Nalls, Mike A , Qi, Yue A , Li, Ziyi , Fratta, Pietro , Johnson, Nicholas L , Oskarsson, Björn , Dickson, Dennis W. , Qi, Yue

Mayo Clinic

Genomics, Proteomics & Bioinformatics | November 22, 2024 | Volume: 22 | Issue: 6 | Pages: No page available

10.1093/gpbjnl/qzae083 | PMID 39576693 Get It

Abstract Mass spectrometry (MS) is a technique widely employed for the identification and characterization of proteins, with personalized medicine, systems biology, and biomedical applications. The application of MS-based proteomics advances our understanding of protein function, cellular signaling, and complex biological systems. MS data analysis is a critical process that includes identifying and quantifying proteins and peptides and then exploring their biological functions in downstream analyses. To address the complexities associated with MS data analysis, we developed ProtPipe to streamline and automate the processing and analysis of high-throughput proteomics and peptidomics datasets with DIA-NN preinstalled. The pipeline facilitates data quality control, sample filtering, and normalization, ensuring robust and reliable downstream analyses. ProtPipe provides downstream analyses, including protein and peptide differential abundance identification, pathway enrichment analysis, protein–protein interaction analysis, and major histocompatibility complex (MHC)–peptide binding affinity analysis. ProtPipe generates annotated tables and visualizations by performing statistical post-processing and calculating fold changes between predefined pairwise conditions in an experimental design. It is an open-source, well-documented tool available at https://github.com/NIH-CARD/ProtPipe, with a user-friendly web interface.
Contemporary Outcomes of TAVR Using a Balloon-Expandable Valve in Patients With Severe Mitral Stenosis: Insights From the Transcatheter Valve Therapies Registry
Ahmad, Imran, Flaherty, James D. , Nagaraja, Vinayak , Huded, Chetan , Reed, Grant W. , Puri, Rishi , Rassi, Andrew N., Goel, Sachin S. , Jneid, Hani , Zahr, Firas , Krishnaswamy, Amar , Kumar, Anirudh , Flaherty, James D , Nagaraja, Vinayak , Huded, Chetan P , Reed, Grant W , Puri, Rishi , Goel, Sachin S , Jneid, Hani , McCabe, James M , Guerrero, Mayra E , Zahr, Firas , Krishnaswamy, Amar , Kapadia, Samir , Ahmad, Imran N., Guerrero, Mayra , Kapadia, Samir

Mayo Clinic

Circulation: Cardiovascular Interventions | November 22, 2024 | Volume: 17 | Issue: 12 | Pages: No page available

10.1161/circinterventions.124.014216 | PMID 39575576 Get It

BACKGROUND: While initial data for transcatheter aortic valve replacement (TAVR) in aortic stenosis patients with mitral stenosis (MS) suggested a poor short-term prognosis, outcomes for contemporary balloon-expandable valves remain unknown. The aim of this retrospective multicenter registry study was to compare the potential impact of MS on TAVR outcomes with balloon-expandable valves. METHODS: Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry and Centers for Medicare & Medicaid Services claims data were used to obtain a cohort of 327 925 patients who underwent TAVR with current balloon-expandable valves (SAPIEN 3, SAPIEN 3 Ultra, or SAPIEN 3 Ultra Resilia) between June 2015 and December 2022 across 791 sites. Severe MS (defined as >10 mm Hg mean gradient or <1.5 cm 2 area) was compared with mild or less MS (defined as <5 mm Hg mean gradient and >2 cm 2 area) using propensity matching to minimize confounding variables. RESULTS: Patients with severe MS (n=8500; 2.6%) had a higher number of comorbid conditions, Society of Thoracic Surgeons risk scores, and were more often women than patients with mild or less MS at the time of index TAVR. While patients with severe MS had worse outcomes at 30 days, when propensity-matched, patients exhibited similar 30-day rates of death (3.2% versus 3.0%), stroke (2.4% versus 2.2%), major vascular complications (1.6% versus 1.6%), device implant success (98.9% versus 99.2%), and new dialysis (0.7% versus 0.5%), with higher rates of pacemaker implantation (11.3% versus 9.4%; P <0.001). By 1 year, there was no difference in the change in the KCCQ (Kansas City Cardiomyopathy Questionnaire) overall score from baseline to 1 year (30.7±27.0 versus 31.9±27.0; P =0.07). By 3 years, an increase in the mortality rate (45.1% versus 40.9%; P <0.001) of patients with severe MS was observed. CONCLUSIONS: MS in isolation is not associated with worsened short-term outcomes among patients undergoing contemporary TAVR with balloon-expandable valves.
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Mellinghoff, Ingo K. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Gordon, Gary, Lassman, Andrew B. , Lim, Michael , Perry, James , Wen, Patrick Y. , Yung, W.K. Alfred , Berry, Nicholas , Graves, Todd, Detry, Michelle A. , Hyddmark, Emma Maria Viktoria, Johnsson, Adam, Kling, Heather M., Powell, Ashley A., Untch, Sarah, Aquilanti, Elisa , Blondin, Nicholas, Boulmay, Brian C., Fuente, Macarena de la, Lobbous, Mina , Mikkelsen, Tom , Newton, Herbert B. , Schiff, David , Sherman, Wendy, Weathers, Shiao-Pei, Friend, John, Lee, E., Mellinghoff, Ingo K , Cloughesy, Timothy F. , Alexander, Brian M. , Cavenee, Webster K. , Colman, Howard , Groot, John de , Ellingson, Benjamin M. , Khasraw, Mustafa , Sulman, Erik P. , Weller, Michael , Wen, Patrick Yung , Johnsson, Adam, McGlothlin, Anna , Powell, Ashley, Drappatz, Jan , Jordan, Justin T. , Kaley, Thomas , Owen, Scott , Peters, Katherine B. , Schiff, David, Weathers, Shiao‐Pei , Youssef, Michael , Friend, John

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1302 Get It

Abstract GBM AGILE(NCT03970447) is a phase 2/3 Bayesian adaptive registration platform trial testing multiple therapies against a common control. Paxalisib, a PI3K/mTOR inhibitor, is the 3rd arm in the trial to conclude evaluation. METHODS Paxalisib was open to patients with newly diagnosed unmethylated (NDU) and recurrent (RD) glioblastoma, with three possible signatures: NDU, RD, and All(NDU+RD). Arm enrollment occurred Dec2020 through May2022. Control patients were enrolled from study initiation (July2019) and were treated with temozolomide(NDU) or lomustine(RD). GBM AGILE investigational arms have 1 or 2 stages, with adaptive randomization in stage 1 and fixed randomization if arms continue to stage 2. Efficacy is based on OS hazard ratio(HR) of Arm/Control. Efficacy goal is final Bayesian probability ≥ 98% for HR&lt;1.00 in combined Stages. An Arm continues to Stage 2 if Bayesian predictive power (PP) ≥ 0.8. An Arm stops accruing in Stage 1 if it reaches maximal sample size(N) or does not meet a minimum efficacy threshold (PP&lt;0.25 for all signatures when N&gt;50). Clinical cut-off is 12 months after accrual stops. The maximum N for paxalisib was approximately 150(Stage 1) and 50(Stage 2). RESULTS After paxalisib reached &gt;150 patients in Stage 1, accrual stopped [Paxalisib/control N 54/75(NDU), 100/188(RD)]. Neither PP thresholds for moving to Stage 2 nor stopping for minimum efficacy were met. Following an unplanned public disclosure that the arm did not continue to stage 2, clinical cut-off for final analysis (planned May2023) was updated to public disclosure date (August2022). At final analysis mean HRs were 0.89(NDU), 1.25(RD), 1.05(All), probabilities of HR&lt;1.00 of 0.72(NDU), 0.076(RD), 0.398(All). Model estimated median OS paxalisib/control (months) were 14.77/13.84(NDU) and 8.58/10.06(RD). CONCLUSION Paxalisib did not show survival benefit over cumulative control in final primary analysis; additional secondary analyses are being considered. GBM AGILE continues to rapidly and efficiently assess therapies in ND and RD glioblastoma.
Utility of the 2019 EULAR/ACR SLE classification criteria for predicting mortality and hospitalisation: development and cross-validation of ominosity score
Figueroa‐Parra, Gabriel , Hanson, Andrew C. , Sánchez-Rodríguez, Alain , Meade‐Aguilar, José A. , Cuéllar‐Gutiérrez, María C. , Duarte‐García, Alí , Crowson, Cynthia S. , González-Treviño, Mariana, Cuéllar-Gutiérrez, María C, Duarte-García, Alí , Crowson, CS , Figueroa-Parra, Gabriel , Meade-Aguilar, Jose Antonio , González‐Treviño, Mariana , Barbour, Kamil E

Mayo Clinic

RMD Open | November 21, 2024 | Volume: 10 | Issue: 4 | Pages: e004833

10.1136/rmdopen-2024-004833 | PMID 39572074 Get It

Objective The 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria score (≥20 points) has been associated with poor outcomes. We aimed to evaluate its utility as a predictor for mortality and hospitalisation and to derive and validate an ominosity score based on the SLE classification criteria set. Methods Incident patients with SLE in a population-based cohort were included. The association between the 2019 EULAR/ACR SLE score and mortality and hospitalisation was assessed using Cox regression adjusted for age, sex and calendar year. An ominosity score for mortality was developed based on the SLE criteria set. The least absolute shrinkage and selection operator method was used to estimate model coefficients. Concordance and calibration were assessed by cross-validation and by plotting the observed event rates against the deciles of predicted probabilities. Results Among 374 patients with incident SLE, a EULAR/ACR score ≥20 points was not associated with an increased risk of mortality (HR 1.17, 95% CI 0.67 to 2.03) or first hospitalisation (HR 1.14, 95% CI 0.79 to 1.64) compared with a score ≤19 points. The derived ominosity score for mortality included age, sex, thrombocytopaenia, neuropsychiatric manifestations, subacute cutaneous or discoid lupus, non-scarring alopecia, inflammatory arthritis, renal involvement, antiphospholipid antibodies and hypocomplementaemia. This model demonstrated a concordance=0.76 with adequate calibration. Age and sex were the main predictors, as seen in the model including just age, sex and year (concordance=0.77). Conclusion The 2019 EULAR/ACR SLE criteria score was not associated with mortality and hospitalisation. The derived ominosity score for mortality presented good prediction for mortality but was not better than age and sex alone.
Senescence Biomarkers and Trajectories of Frailty and Physical Function After Kidney Transplantation
Lorenz, Elizabeth C. , Smith, Byron H. , Wadei, Hani M. , Mour, Girish , Kennedy, Cassie C. , Schinstock, Carrie A. , Kremers, Walter K. , Cheville, Andrea , Hickson, LaTonya J. , Atkinson, Elizabeth J. , White, Thomas A. , Cheville, Andrea L , Rule, Andrew D , LeBrasseur, Nathan K , Smith, Byron , Hickson, LaTonya J , Schinstock, Carrie , Kennedy, Cassie C , Wadei, Hani M , Kremers, Walter K , Mour, Girish K , Rule, Andrew D. , LeBrasseur, Nathan K.

Mayo Clinic

Clinical Transplantation | November 20, 2024 | Volume: 38 | Issue: 11 | Pages: No page available

10.1111/ctr.70022 | PMID 39564682 Get It

ABSTRACTCellular senescence is a biological mechanism of aging and age‐related diseases. The aim of this study was to examine whether senescence biomarkers are associated with frailty and physical function trajectories in patients undergoing kidney transplantation (KT). We also discussed the relationship between senescence biomarkers and KT function. In this multicenter study, we prospectively assessed plasma levels of senescence biomarkers, frailty as measured by the Physical Frailty Phenotype, and physical function as measured by the Short Physical Performance Battery prior to KT. Frailty, physical function, and KT function were also measured 1 year after KT. Variable associations were assessed using Cox and relaxed least absolute shrinkage and selection operation regression. The cohort consisted of 197 participants (mean age 53 ± 13 years, 61.4% male, and 80.2% White race). Higher pre‐KT levels of macrophage‐derived chemokine (MDC/CCL22) and growth differentiation factor‐15 (GDF‐15) were independently associated with less improvement in frailty and/or physical function during the first year after KT. Higher pre‐KT levels tumor necrosis factor receptor superfamily member 6 (FAS) and MMP‐9 levels were independently associated with lower KT function one year after KT. Pre‐KT cellular senescence may contribute to frailty, physical function, and kidney function trajectories during the first year after KT.